Notice of Intent

THIS IS NOT A REQUEST FOR QUOTE - THIS IS A NOTICE OF THE GOVERNMENT'S INTENT TO ISSUE A SOLE SOURCE AWARD TO IMMUNALYSIS CORPORATION TO ASSIST THE OFFICE OF THE UNDER SECRETARY OF DEFENSE FOR PERSONNEL AND READINESS WITH MISSION CRITICAL SUPPORT. WHS Acquisition Directorate intends to issue a contract to Immunalysis Corporation on a sole source basis under authority of FAR 6.302-1(a)(2), Only One Responsible Source and No Other Supplies or Services Will Satisfy Agency Requirements. The Department of Defense (DoD) Drug Demand Reduction Program (DDRP) was mandated in 1981 and given the mission to deter DoD personnel from using prohibited drugs. The DoD DDRP policy for military service members is promulgated in DoD Directive 1010.1, with detailed guidance concerning drug testing procedures contained in DoD Directive 1010.16. The DoD DDRP is aligned with DoD policies that pertain to health and readiness within the Office of the Under Secretary of Defense for Personnel and Readiness. DDRP's mission involves compulsory random drug testing with punitive consequences, anti-drug education, and treatment. The effectiveness of this program is measured by monitoring the prevalence of drug use from drug testing statistics published annually. DDRP conducts testing at six DoD Forensic Toxicology Drug Testing Laboratories (FTDTLs), as well as the Forensic Toxicology Laboratory of the Armed Forces Medical Examiner System (FORTOX-AFMES). Each location currently uses the Hitachi / Roche D-Modular Analyzer System(s) to perform mission critical testing. There are approximately 24 D-Modular systems spread throughout DDRP's testing environment. The Government has invested approximatly $4.32M in its existing instrumentation which enables DDRP to meet mission goals. The DDRP has a mission critical requirement to test the use of synthetic cannabinoids by members of the Military Services. As such, this effort is to procure immunoassay reagents to be used on the Government's existing Hitachi / Roche instrumentation to meet the Government's need. (Note: There is currently not a requirement to replace the existing analyzer systems.) Since the introduction and widespread use of synthetic cannabinoids into the drug culture, the DDRP has conducted a joint effort with the National Institute of Drug Abuse and AFMES to identify a strategy to deter and detect the use of synthetic cannabinoids by military personnel. In the course of this effort, Immunalysis Corporation was identified as the only manufacturer of an immunoassay reagent capable of identifying the broad class of synthetic cannabinoid parent and/or metabolites found in urine as a result of synthetic cannabinoid abuse on the existing analyzer systems currently in use at the FTDTLs and FORTOX-AFMES. Therefore, the initial contract action will be established with Immunalysis Corporation as an indefinite delivery/indefinite quantity (IDIQ) contract for a period of 12 months, from approximately 04 MAR 2013 through 28 FEB 2014, and will include four (4) 12 month option periods. WHS Acquisition Directorate anticipates issuing firm fixed price delivery orders under this contract to meet the mission critical needs of DDRP. The estimated minimum base order amount is $47,000.00 and the not-to-exceed maximum total is $1.6M including all options. This notice of intent is not a request for competitive proposals. Any response to this notice must show clear and convincing evidence that another manufactured immunoassay reagent capable of identifying the broad class of synthetic cannabinoid parent and or metablites found in urine as a result of synthetic cannabinoid abuse is compatible with the existing Hitachi / Roche D-Modular Analyzer System(s). If no affirmative written response is received, the contract will be issued without further notice. Interested parties may identify their capabilities with respect to this requirement by 26 February 2013, at 12:00 p.m. Eastern Standard Time. All information received will be considered by the Government. A determination by the Government not to compete this action based on this notice is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement. The primary North American Industry Classification System (NAICS) code is 424210 (Diagnostic reagents merchant wholesalers).